Anúncio
Anúncio
BCAX
Bicara Therapeutics Inc. Common Stock
17.96
USDPatrocinado
+1.40
+8.45%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
18.83
+0.87
+4.84%
Relatórios de Lucros BCAX
Rácio de surpresa positiva
BCAX separação 1 de 5 últimas estimativas.
20%
Próximo Relatório
Data do Próximo Relatório
24 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.69
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+2.99%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/+76.92%
Bicara Therapeutics Inc. Common Stock earnings per share and revenue
On 10 de nov. de 2025, BCAX reported earnings of -0.67 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -19.60% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of -0.69 USD, with revenue projected to reach -- USD, implying an aumentar of 2.99% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Bicara Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bicara Therapeutics Inc. Common Stock reported EPS of -$0.67, missing estimates by -19.6%, and revenue of $0.00, 0% as expectations.
How did the market react to Bicara Therapeutics Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.85%, changed from $14.64 before the earnings release to $13.93 the day after.
When is Bicara Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for 24 de mar. de 2026.
What are the forecasts for Bicara Therapeutics Inc. Common Stock's next earnings report?
Based on 13
analistas, Bicara Therapeutics Inc. Common Stock is expected to report EPS of -$0.69 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio